| CRASH points |
| 0 |
1 |
2 |
| Ado-trastuzumab emtansine (TD-M1) |
Bendamustine 90mg/m2 + R |
5-FU/LV (Roswell-Park) |
| Capecitabine 2g/m2 |
Capecitabine 2.5g/m2 |
5-FU/LV (Mayo) |
| Cisplatin/pemetrexed |
Carboplatin/gemcitabine AUC 4-6/1g d1,d8 |
5-FU/LV + bevacizumab |
| Dacarbazine |
Carboplatin/pemetrexed |
AC (and AC-paclitaxel and Keynote 522 regimen by extension) |
| Docetaxel weekly |
Carboplatin/paclitaxel q3w |
CAF |
| Enfortumab-vedotin |
Cisplatin/gemcitabine 25/1000 d1,8 |
Carboplatin/docetaxel q3w |
| Fam-trastuzumab deruxtecan |
ECF |
CHOP |
| FOLFIRI |
Fludarabine |
Cisplatin/docetaxel 75/75 |
| Gemcitabine 1g 3/4 weeks |
FOLFIRI+ bevacizumab or panitumumab |
Cisplatin/etoposide |
| Gemcitabine 1.25g 3/4 weeks |
FOLFOX 85mg/m2 +/-bevacizumab or cetuximab |
Cisplatin/gemcitabine d1,8,15 |
| Paclitaxel weekly |
Gemcitabine 7/8 weeks then 3/4 |
Cisplatin/paclitaxel 135-24h q3w |
| Pemetrexed |
Gemcitabine/irinotecan |
CMF classic |
| |
PEG doxorubicin 50 q4w |
Docetaxel q3w |
| |
Topotecan weekly |
Doxorubicin q3w |
| |
XELOX |
FOFLIRINOX (iri180) |
| |
|
FOLFOX 100-130 mg/m2 |
| |
|
Gemcitabine/nab-placlitaxel d1,8,15 |
| |
|
Gemcitabine/pemetrexed d8
Irinotecan q3w
|
| |
|
Paclitaxel q3w |
| |
|
Sacituzumab govitecan |
| |
|
Topotecan monthly |
|
Unless specified otherwise, the doses are per meter squared. If no dose is specified, this means that the various common dosages used for this regimen all fall in the same category (e.g. docetaxel 60, 75, or 100 mg/m2 q3w)
Q3w, q4w: every 3 (4) weeks
|
Regimens not listed should be scored by analogy./
The boundaries between points are: MAX2 < 0.088 = 0; 0.089-0.149 = 1; >0.15 = 2
For more precise numbers (e.g. research purpose), please contact Dr Extermann
|